Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2009 - 2023)

Teva Pharmaceutical Industries (TEVA) has 14 years of Short-Term Debt issuances data on file, last reported at $700.0 million in Q3 2023.

• Quarterly Short-Term Debt issuances changed N/A year-over-year to $700.0 million in Q3 2023, while the trailing twelve-month figure through Dec 2024 was $700.0 million (down 22.22% YoY) and the FY2023 annual result came in at $700.0 million, changed N/A from the prior year.
• Short-Term Debt issuances advanced to $700.0 million in Q3 2023, from $200.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $700.0 million in Q3 2023 to a low of -$1.0 million in Q1 2019.
• A 4-year average of $247.1 million and a median of $200.0 million in 2021 frame the typical range for Short-Term Debt issuances.
• Annual changes were most pronounced in 2019 — Short-Term Debt issuances soared 9900.0% — and 2021, when it tumbled 39.02%.
• Tracing TEVA's Short-Term Debt issuances over 4 years: stood at $406.0 million in 2019, then dropped by 19.21% to $328.0 million in 2020, then plunged by 39.02% to $200.0 million in 2021, then jumped by 250.0% to $700.0 million in 2023.
• The last three Short-Term Debt issuances figures came in at $700.0 million (Q3 2023), $200.0 million (Q4 2021), and $328.0 million (Q4 2020), per Business Quant data.